Tempus Announces Real-World Data-Driven Program to Accelerate Precision Oncology Research

Tempus, a leader in artificial intelligence and precision medicine, today announced Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes a number of medical centers that are leveraging the program to advance its research, including Allegheny Health Network, Baylor College of Medicine, Rush University Medical Center, Stanford Cancer Center, TriHealth, UCLA Jonsson Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, and University of North Carolina Lineberger Comprehensive Cancer Center.

“The Tempus platform is uniquely positioned to provide the resources necessary to create a clear path for collaborative research,” said Mike Thompson, MD, PhD, Vice President of Clinical Partnerships at Tempus. “The institutions that are already leveraging Tempus+ have experienced the program’s ability to accelerate their critical work, and we look forward to seeing it reach its full potential.”

Researchers at participating institutions gain access to Tempus’ library of more than five million de-identified research records through the company’s data analytics platform, Lens, to identify patterns and insights, define and test their hypotheses, and eventually investigate and potentially publish their research. Tempus+ is creating a sustainable and secure infrastructure to collect and analyze the data required to foster research that can inform the future of clinical care.

“With more readily available next-generation sequencing and other molecular profiling technologies, we are gaining increasing insights into the pathogenesis of disease, prognostic stratification, and potentially actionable sarcoma alterations. Tempus+ has one of the largest comprehensive molecular profiling databases of sarcoma across all histologic subtypes and age ranges,” said Noah Federman, MD, Professor and Director of the UCLA Pediatric Sarcoma Program. “I am just so excited to be able to work with Tempus+ and collaborators across the country to be able to interrogate this enormous annotated resource.” 

“Today large numbers of cancer patients are having their cancers analyzed for genetic alterations, some of which may drive the tumors’ growth and spread,” said Timothy M. Kuzel, MD, FACP, Division Chief of Hematology/Oncology/Cell Therapy at Rush University Medical Center. “By having access to these large datasets accumulated from hundreds of centers, including clinical data points such as treatments given and the responses they provide, Rush physicians and researchers can use these clues to develop the next generation of treatments for our patients.”

“Our clinicians and scientists are excited to use Tempus+ as a platform to complement our internal precision oncology initiatives,” remarked Quintin Pan, PhD, Deputy Director and Coleman Chair in Cancer Research & Therapeutics at University Hospitals Seidman Cancer Center. “Having access to a robust real-world cancer patient dataset will allow us to better understand how to deliver the best care to every cancer patient at the appropriate time.”

To learn more about Tempus+, visit

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit

Related Content

View more
  • post image

    Accelerate clinical trial enrollment and site activation

    Learn how TriHealth uses the TIME network to identify trial subjects and rapidly activate new clinical trials within its oncology portfolio within an average of ~10 business days.

    Watch replay
  • post image

    Tempus’ FDA approval and insights on the use of companion diagnostics in clinical development

    Tempus has recently announced the PMA approval for xT CDx, our solid tumor CDx and 648 gene panel.

    In this webinar, you will hear how the Tempus platform can support development of new therapies by combining real-world data, next-generation sequencing, and artificial-intelligence to advance precision oncology. Our regulatory and scientific experts will provide an overview of the pathways for diagnostics and share best practices for biopharma and biotech sponsors to consider in clinical trial design and the development of companion diagnostics.

    Watch replay
  • post image

    Using TIME to accelerate trial enrollment for Aadi Bioscience

    The Tempus TIME program provided Aadi access to a network of providers and patients to accelerate enrollment for its PRECISION 1 TSC1/TSC2 phase 2 clinical trial. Read on to learn how the TIME program decreased time to enroll with the just-in-time activation of ~10 business days.

    Read more